<DOC>
	<DOCNO>NCT01618825</DOCNO>
	<brief_summary>This open Label , randomize , two-period , two-treatment , two-sequence , crossover , balance , single dose pivotal study . The purpose study assess bioequivalence Test Product correspond Reference Product fed condition healthy adult human subject .</brief_summary>
	<brief_title>Bioequivalence Study Lamotrigine Tablets 25 mg ( 2 x 25 mg Tablets ) Under Fed Condition</brief_title>
	<detailed_description>Objective pivotal study assess bioequivalence Test Product : Lamotrigine Tablets 25 mg ( 2 x 25 mg ) M/s Ipca Laboratories Limited , India correspond Reference Product : LAMICTAL® ( Lamotrigine ) Tablets 25 mg ( 2 x 25 mg ) GlaxoSmithkline , USA , feed condition healthy adult human subject randomize crossover study . The study conduct 28 healthy adult subject . In study period , single 2 X 25 mg dose either test reference administer subject per randomization schedule study period 240 mL water ambient temperature sit position . The duration clinical phase approximately 26 day include washout period least 21 day administration study drug study period .</detailed_description>
	<mesh_term>Lamotrigine</mesh_term>
	<mesh_term>Anticonvulsants</mesh_term>
	<criteria>1 . Age : 18 45 year old , inclusive . 2 . Sex : Males and/or nonpregnant , nonlactating female . A . Females childbearing potential must negative serum beta human chorionic gonadotropin ( βHCG ) pregnancy test perform within 21 day prior initiation study &amp; prior checkin period . They must use acceptable form contraception . B . Acceptable form contraception include follow : . Intrauterine device place least 3 month prior start study remain place study period , ii . Barrier method contain use conjunction spermicidal agent , iii . Surgical sterilization iv . Practicing sexual abstinence throughout course study . C. Females consider childbearing potential one one following report documented medical history : i. Postmenopausal spontaneous amenorrhea least one year , ii . Bilateral oophorectomy without hysterectomy absence bleed least 6 month , iii . Total hysterectomy absence bleed least 3 month . 3 . BMI : 18.5 24.9 weight Kg / ( height meter ) 2 inclusive ; BMI value round one significant digit decimal point ( e.g . 24.94 round 24.9. 18.45 round 18.5 ) . 4 . Able communicate effectively study personnel willingness follow protocol requirement evidence write informed consent . 5 . Able give write informed consent participate study . 6 . All volunteer must judge principal coinvestigator physician normal healthy prestudy safety assessment perform within 21 day first dose study medication include : 1 . A physical examination clinically significant finding . 2 . Results within normal limit clinically nonsignificant test mention list Laboratory Parameters : Additional test and/or examination may perform , necessary , base Principal Investigator discretion . All result assess laboratory normal range current time test copy normal range use include study documentation . 1 . History allergic response Lamotrigine relate drug , formulation ingredient . 2 . Have significant disease clinically significant abnormal finding screen , [ medical history , physical examination , laboratory evaluation , ECG , chest Xray recording , obstetrics gynecological history examination along PAP smear ( female volunteer ) &amp; transvaginal ultrasonography ( female volunteer ) ] . 3 . Any disease condition might compromise haemopoeitic gastrointestinal , renal , hepatic , cardiovascular , respiratory , central nervous system , diabetes , psychosis body system . 4 . History presence bronchial asthma . 5 . Use hormone replacement therapy within 3 month prior study medication dosing . 6 . A depot injection implant drug within 3 month prior administration study medication . 7 . Use enzymemodifying drug within 30 day prior receive first dose study medication . 8 . History evidence drug dependence alcoholism moderate alcohol use . 9 . Smokers smoke 10 cigarette per day 20 biddy per day refrain smoke study period . 10 . History difficulty donate blood difficulty accessibility vein . 11 . History allergic response heparin . 12 . A positive hepatitis screen ( include subtypes B &amp; C ) . 13 . A positive test result HIV antibody / syphilis ( RPR/VDRL ) . 14 . Volunteers donate blood ( 1 unit 450 ml ) within 90 day prior initial dose study drug blood loss , exclude volume drawn screen study drug . 15 . History difficulty swallowing , gastrointestinal disease could affect drug absorption . 16 . Intolerance venipuncture . 17 . Any food allergy , intolerance , restriction special diet , opinion Principal Investigator , could contraindicate volunteer 's participation study . 18 . Volunteers receive known investigational drug within five elimination half life administer drug prior initial dose study drug participate clinical drug study bioequivalence study within 90 day prior initial dose study drug , whichever great . 19 . Found positive urine test drug abuse do checkin period I .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>